Lacosamide in monotherapy in BTRE (brain tumor-related epilepsy): results from an Italian multicenter retrospective study.

Acetamides Anticonvulsants / therapeutic use Brain Neoplasms / complications Drug-Related Side Effects and Adverse Reactions Epilepsies, Partial / complications Epilepsy / complications Humans Lacosamide / therapeutic use Quality of Life Retrospective Studies Seizures / drug therapy Treatment Outcome
Epilepsy Lacosamide Primary brain tumor Seizure freedom Side effects

Journal

Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335

Informations de publication

Date de publication:
May 2022
Historique:
received: 21 01 2022
accepted: 24 03 2022
pubmed: 11 4 2022
medline: 10 5 2022
entrez: 10 4 2022
Statut: ppublish

Résumé

Lacosamide (LCM) is a third-generation anti-seizure medication (ASM) approved for focal onset epilepsy in patients aged ≥ 4.378 Previous studies have reported an efficacy of LCM as add-on treatment in brain tumor-related epilepsy (BTRE). To date, there are no studies in the literature focusing on lacosamide used in monotherapy to treat BTRE. In our retrospective study we investigated efficacy and tolerability of LCM in monotherapy in a multicenter national cohort of primary brain tumor patients. We collected from 12 Italian Centers 132 patients with primary brain tumors who were treated with LCM in monotherapy. For each patient we evaluated seizure freedom at 3 and 6 months (primary endpoints), side effects and drop-out rate (secondary endpoints). Overall, LCM led to seizure freedom in 64.4% of patients at 3 months and 55% at 6 months. Patients who used two or more ASMs before LCM had a worse seizure control than patients in monotherapy with LCM as first choice. In 14 patients, we observed seizure control despite tumor progression on magnetic resonance (MRI). Multivariate analysis showed that gross-total resection at diagnosis was significantly associated with higher seizure freedom rate at 6 months. Side effects were mainly mild (grade 1-2 according to CTCAE classification) and drop-out rate was low (1.5%). Main side effects were dizziness and somnolence. This is the first study showing a good efficacy and tolerability of LCM when used in monotherapy in BTRE. Further prospective studies are needed to confirm these preliminary data, investigating also quality of life and neurocognitive functions.

Identifiants

DOI: 10.1007/s11060-022-03998-6 PMID: 35397759
pubmed: 35397759
doi: 10.1007/s11060-022-03998-6
pii: 10.1007/s11060-022-03998-6
doi:

Substances chimiques

Acetamides 0
Anticonvulsants 0
Lacosamide 563KS2PQY5

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

551-559

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Van Breemen MSM, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol 6:421–430. https://doi.org/10.1016/S1474-4422(07)70103-5
doi: 10.1016/S1474-4422(07)70103-5 pubmed: 17434097
Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist 19(7):751–759. https://doi.org/10.1634/theoncologist.2014-0060
doi: 10.1634/theoncologist.2014-0060 pubmed: 24899645 pmcid: 4077452
Rudà R, Bello L, Duffau H, Soffietti R (2012) Seizures in low-grade gliomas: natural history, pathogenesis, and outcome after treatments. Neuro Oncol 14(Suppl 4):iv55–iv64. https://doi.org/10.1093/neuonc/nos199
doi: 10.1093/neuonc/nos199 pubmed: 23095831 pmcid: 3480244
De Bruin ME, van der Meer PB, Dirven L, Taphoom MJB, Koekkoek JAF (2021) Efficacy of antiepileptic drugs in glioma patients with epilepsy: a systematic review. Neurooncol Pract 8(5):501–517. https://doi.org/10.1093/nop/npab030
doi: 10.1093/nop/npab030 pubmed: 34589231 pmcid: 8475226
Perucca E (2013) Optimizing antiepileptic drug treatment in tumoral epilepsy. Epilepsia 54(Suppl 9):97–104. https://doi.org/10.1111/epi.12452
doi: 10.1111/epi.12452 pubmed: 24328881
Kellinghaus C (2009) Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 5:757–766. https://doi.org/10.2147/tcrm.s5189
doi: 10.2147/tcrm.s5189 pubmed: 19816574 pmcid: 2754090
Saria MG, Corle C, Hu J, Rudnick JD, Phuphanich S, Mrugala MM, Crew LK, Bota DA, Dan FuB, Kim RY, Brown T, Feely H, Brechlin J, Brown BD, Drappatz J, Wen PY, Chen CC, Carter B, Lee JW, Kesari S (2013) Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: clinical article. J Neurosurg 118(6):1183–1187. https://doi.org/10.3171/2013.1.JNS12397
doi: 10.3171/2013.1.JNS12397 pubmed: 23451905
Villanueva V, Saiz-Diaz R, Toledo M, Piera A, Mauri JA, Rodriguez-Uranga JJ, López-González FJ, Gómez-Ibáñez A, Garcés M, González de la Aleja J, Rodríguez-Osorio X, Palao-Duarte S, Castillo A, Bonet M, Ruiz-Giménez J, Palau J, Arcediano A, Toledo M, Gago A (2016) NEOPLASM study: Real-life use of lacosamide in patients with brain tumor-related epilepsy. Epilepsy Behav. 65:25–32. https://doi.org/10.1016/j.yebeh.2016.09.033
doi: 10.1016/j.yebeh.2016.09.033 pubmed: 27863278
Maschio M, Zarabla A, Maialetti A, Fabi A, Vidiri A, Villani V, Giannarelli D (2017) Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: a prospective explorative study with a historical control group. Epilepsy Behav 73:83–89. https://doi.org/10.1016/j.yebeh.2017.05.031
doi: 10.1016/j.yebeh.2017.05.031 pubmed: 28623754
Rudà R, Pellerino A, Franchino F, Bertolotti C, Bruno F, Mo F, Migliore E, Ciccone G, Soffietti R (2018) Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study. J Neurooncol 136(1):105–114. https://doi.org/10.1007/s11060-017-2628-0
doi: 10.1007/s11060-017-2628-0 pubmed: 29030718
Rudà R, Houillier C, Maschio M, Reijneveld JC, Hellot S, De Backer M, Chan J, Joeres L, Leunikava I, Glas M, Grant R (2020) Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). Epilepsia 61(4):647–656. https://doi.org/10.1111/epi.16486
doi: 10.1111/epi.16486 pubmed: 32329527 pmcid: 7384112
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 world health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820. https://doi.org/10.1007/s00401-016-1545-1
doi: 10.1007/s00401-016-1545-1 pubmed: 27157931
Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL, Nordli DR, Perucca E, Tomson T, Wiebe S, Zhang YH, Zuberi SM (2017) ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology. Epilepsia 58(4):512–521. https://doi.org/10.1111/epi.13709
doi: 10.1111/epi.13709 pubmed: 28276062 pmcid: 5386840
Van Opijen MP, van der Meer PB, Dirven L, Fiocco M, Kouwenhoven MCM, van den Bent MJ, Taphoorn MJB, Koekkoek JAF (2021) The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. J Neurooncol 154(1):73–81. https://doi.org/10.1007/s11060-021-03800-z
doi: 10.1007/s11060-021-03800-z
Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, Muti P (2011) Levetiracetam monotherapy in patients with brain tumor-related epilepsy: seizure control, safety, and quality of life. J Neurooncol 104:205–214. https://doi.org/10.1007/s11060-010-0460-x
doi: 10.1007/s11060-010-0460-x pubmed: 21107994
Rosati A, Buttolo L, Stefini R, Todeschini A, Cenzato M, Padovani A (2010) Efficacy and safety of levetiracetam in patients with glioma: a clinical prospective study. Arch Neurol 67(3):343–346. https://doi.org/10.1001/archneurol.2009.335
doi: 10.1001/archneurol.2009.335 pubmed: 20212232
Wagner GL, Wilms EB, Van Donselaar CA, Vecht ChJ (2003) Levetiracetam: preliminary experience in patients with primary brain tumours. Seizure 12:585–586. https://doi.org/10.1016/s1059-1311(03)00096-7
doi: 10.1016/s1059-1311(03)00096-7 pubmed: 14630498
Lim DA, Tarapore P, Chang E, Burt M, Chakalian L, Barbaro N, Chang S, Lamborn KR, McDermott MW (2009) Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: a randomized phase II pilot study. J Neurooncol 93:349–354. https://doi.org/10.1007/s11060-008-9781-4
doi: 10.1007/s11060-008-9781-4 pubmed: 19169651 pmcid: 2687520
Newton HB, Goldlust SA, Pearl D (2006) Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78:99–102. https://doi.org/10.1007/s11060-005-9070-4
doi: 10.1007/s11060-005-9070-4 pubmed: 16541329
Vecht C, Duran-Peña A, Houillier C, Durand T, Capelle L, Huberfeld G (2017) Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol 133:603–607. https://doi.org/10.1007/s11060-017-2473-1
doi: 10.1007/s11060-017-2473-1 pubmed: 28492978
Kerkhof M, Dielemans JC, van Breemen MS, Zwinkels H, Walchenbach R, Taphoorn MJ, Vecht CJ (2013) Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme. Neuro Oncol 15:961–967. https://doi.org/10.1093/neuonc/not057
doi: 10.1093/neuonc/not057 pubmed: 23680820 pmcid: 3688020
Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based management. Oncologist 19:751–759. https://doi.org/10.1634/theoncologist.2014-0060
doi: 10.1634/theoncologist.2014-0060 pubmed: 24899645 pmcid: 4077452
Maschio M, Dinapoli L, Sperati F, Fabi A, Pace A, Vidiri A, Muti P (2012) Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: open-label pilot study for assessing the efficacy, tolerability and impact on quality of life. J Neurooncol 106:651–656. https://doi.org/10.1007/s11060-011-0689-z
doi: 10.1007/s11060-011-0689-z pubmed: 21847705
Mauro AM, Bomprezzi C, Morresi S, Provinciali L, Formica F, Iacoangeli M, Scerrati M (2007) Prevention of early postoperative seizures in patients with primary brain tumors: Preliminary experience with oxcarbazepine. J Neurooncol 81:279–285. https://doi.org/10.1007/s11060-006-9229-7
doi: 10.1007/s11060-006-9229-7 pubmed: 16944312
Maschio M, Dinapoli L, Zarabla A, Pompili A, Carapella CM, Pace A, Giannarelli D, Occhipinti E, Jandolo B (2008) Outcome and tolerability of topiramate in brain tumor associated epilepsy. J Neurooncol 86:61–70. https://doi.org/10.1007/s11060-007-9430-3
doi: 10.1007/s11060-007-9430-3 pubmed: 17598071
van Breemen MSM, Rijsman RM, Taphoorn JB, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256:1519–1526. https://doi.org/10.1007/s00415-009-5156-9
doi: 10.1007/s00415-009-5156-9 pubmed: 19434440
Faramand AM, Barnes N, Harrison S, Gunny R, Jacques T, Tahir MZ, Varadkar SM, Cross HJ, Harkness W, Tisdall MM (2018) Seizure and cognitive outcomes after resection of glioneuronal tumors in children. Epilepsia 59:170–178. https://doi.org/10.1111/epi.13961
doi: 10.1111/epi.13961 pubmed: 29178251
Southwell DG, Garcia PA, Berger MS, Barbaro NM, Changet EF (2012) Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 70:1406–1413. https://doi.org/10.1227/NEU.0b013e3182500a4c (discussion 1413–1414)
doi: 10.1227/NEU.0b013e3182500a4c pubmed: 22353798
Xiangrong L, Chengjun W, Zhiqin L, Meng Z, Xiaohui R, Xiaohui Z et al (2020) Risk factors and control of seizures in 778 Chinese patients undergoing initial resection of supratentorial meningiomas. Neurosurg Rev 43:597–608. https://doi.org/10.1007/s10143-019-01085-5
doi: 10.1007/s10143-019-01085-5
Berntsson SG, Merrell RT, Amirian ES, Armstrong GN, Lachance D, Smits A, Jiang Z (2018) Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case–control study. J Neurol 265:1432–1442. https://doi.org/10.1007/s00415-018-8857-0
doi: 10.1007/s00415-018-8857-0 pubmed: 29687214 pmcid: 5990563
Chang EF, Potts MB, Keles GE, Lamborn KR, Chang SM, Barbaro NM, Berger MS (2008) Seizure characteristics and control following resection in 332 patients with low-grade gliomas. J Neurosurg 108:227–235. https://doi.org/10.3171/JNS/2008/108/2/0227
doi: 10.3171/JNS/2008/108/2/0227 pubmed: 18240916
Chaichana KL, Parker SL, Olivi A, Quiñones-Hinojosa A (2009) Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. J Neurosurg 111:282–292. https://doi.org/10.3171/2009.2.JNS081132
doi: 10.3171/2009.2.JNS081132 pubmed: 19344222

Auteurs

F Mo (F)

Division of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy. francy.mo91@gmail.com.
ORCID: 0000-0002-8469-7567

S Meletti (S)

Division of Neurology, Modena University Hospital, Modena, Italy.
Center for Neuroscience and Neurotechnology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.

V Belcastro (V)

Division of Neurology, Maggiore Hospital, Lodi, Italy.

S Quadri (S)

Division of Neurology, ASST Papa Giovanni XXIII of Bergamo, Bergamo, Italy.

M Napolitano (M)

Division of Neurology and Stroke Unit, Hospital A. Cardarelli, Napoli, Italy.

L Bello (L)

Division of Neurosurgical Oncology, Department of Oncology and Hemato-Oncology, Università Degli Studi Di Milano, Milan, Italy.

F Dainese (F)

Division of Neurology, Epilepsy Centre, Hospital of Venezia, Venice, Italy.

M Scarpelli (M)

Division of Neurology, Department of Neuroscience, AOUI Verona, Verona, Italy.

I Florindo (I)

Division of Neurology, Hospital of Parma, Parma, Italy.

A Mascia (A)

IRCCS Neuromed, Pozzilli, Italy.

G Pauletto (G)

Neurology Unit, Department of Neuroscience, "S. Maria Della Misericordia" University Hospital, Udine, Italy.

F Bruno (F)

Division of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy.

A Pellerino (A)

Division of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy.

G Giovannini (G)

Division of Neurology, Modena University Hospital, Modena, Italy.
Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.

M Polosa (M)

Division of Neurosurgery, ASST Lariana, Como, Italy.

M Sessa (M)

Division of Neurology, ASST Papa Giovanni XXIII of Bergamo, Bergamo, Italy.

M Conti Nibali (M)

Division of Neurosurgical Oncology, Department of Oncology and Hemato-Oncology, Università Degli Studi Di Milano, Milan, Italy.

G Di Gennaro (G)

IRCCS Neuromed, Pozzilli, Italy.

G L Gigli (GL)

Department of Medicine (DAME), University of Udine, Udine, Italy.
Clinical Neurology Unit, "S. Maria Della Misericordia" University Hospital, Udine, Italy.

A Pisanello (A)

Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS Di Reggio Emilia, Reggio Emilia, Italy.

F Cavallieri (F)

Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, Modena, Italy.
Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS Di Reggio Emilia, Reggio Emilia, Italy.

R Rudà (R)

Division of Neuro-Oncology, Dept. Neuroscience, University and City of Health and Science Hospital, Via Cherasco 15, 10126, Torino, Italy.
Division of Neurology, San Giacomo Hospital, AULSS2 Marca Trevigiana (TV), Treviso, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Acétamides › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Anticonvulsivants › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Maladies du système nerveux › Tumeurs du système nerveux › Tumeurs du système nerveux central › Tumeurs du cerveau › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Troubles dus à des produits chimiques › Effets secondaires indésirables des médicaments › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux central › Encéphalopathies › Épilepsie › Épilepsies partielles › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Maladies du système nerveux › Maladies du système nerveux central › Encéphalopathies › Épilepsie › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Acétamides › Lacosamide › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Démographie › État de santé › Qualité de vie › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Manifestations neurologiques › Crises épileptiques › Lacosamide in monotherapy in BTRE (brain...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Lacosamide in monotherapy in BTRE (brain...